S
Symbiotec Pharmalab
Biotechnology · India · Founded 2002
Api manufacturing company that develops and markets research-based cortico steroids MoreLess
Symbiotec, based in Indore, Central India, specializes in the development, production, and marketing of research-based Cortico Steroids and Steroid Hormone Active Pharmaceutical Ingredients (APIs). The company leverages its collective expertise to create innovative pharmaceutical solutions aimed at enhancing patient health. Symbiotec serves a global clientele, including pharmaceutical companies and healthcare providers, operating in the highly specialized market of steroid APIs. The business model revolves around extensive research and development (R&D), followed by the commercialization of high-quality, reliable APIs. Revenue is generated through the sale of these APIs to various stakeholders in the healthcare industry. Symbiotec is committed to sustainable operations and responsible practices, contributing to community health initiatives such as the establishment of a Dialysis Unit at Madhav Srishti SevaNyas in Indore. The company’s strategic focus is on delivering advanced healthcare solutions while maintaining sustainable and ethical operations.
Keywords: Cortico Steroids, Steroid Hormones, APIs, pharmaceutical solutions, patient health, R&D, sustainable operations, healthcare providers, global clientele, Indore.
Company overview
Symbiotec Pharmalab company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2002
- Headquarters
- India
- Employees
- 1,162
- Open positions
- None listed
- Dealroom signal
- 84.6
Valuation & funding
Symbiotec Pharmalab funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SECONDARY✓Other financing | Aug 2026 | $8.8M | — | Think India Opportunities Master Fund · ValueQuest Investment Advisors · WhiteOak Capital Asset Management | ↗ |
| LATE VC✓Equity / VC | Oct 2013 | $48M | $192M | Actis | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 1,172 |
| 2025 | 1,076 |
| 2024 | 888 |
| 2023 | 765 |
| 2022 | 582 |
| 2021 | 391 |
| 2020 | 293 |
Growth signals
Symbiotec Pharmalab website traffic
Latest recorded traffic for Symbiotec Pharmalab is 1.7K monthly website visits, up 54.5% over the last three months. Symbiotec Pharmalab's team grew 8% over the past year.
Comparisons
Symbiotec Pharmalab compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Symbiotec Pharmalab's talent
Source: Dealroom Talent Intelligence.
Investors
4 investors on Symbiotec Pharmalab's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Symbiotec Pharmalab has talent and traffic
team presence
In the news
Latest news about Symbiotec Pharmalab
Recent press, funding announcements, and product moves mentioning Symbiotec Pharmalab — open to read from the original sources.
Market sentiment
What the market is saying about Symbiotec Pharmalab
An AI-synthesized read of the highest-engagement posts about Symbiotec Pharmalab on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Symbiotec Pharmalab’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.